The fundamental problem with developing new medicines to target antimicrobial resistance is, unlike most other medicines, the market is inherently limited by design. In order to slow and control continued antimicrobial resistance, newer medicines are frequently used only in a limited set of circumstances and in only the most necessary cases. This makes it challenging for biopharmaceutical research companies to recoup research and development costs in subsequent sales. Antibiotic stewardship programs are designed to limit the use of new antibiotics specifically for this reason and thus limit the commercial viability of new antimicrobials.